Novo Nordisk Trails 30% Behind Eli Lilly Despite 350% Surge, Aims for Growth

Novo Nordisk A/S and Eli Lilly & Co. are leading the way in the weight-loss drug market, which is growing fast and getting more competitive. Novo Nordisk has Wegovy, and Eli Lilly has Zepbound, which are key players in this competition.

Both companies are working hard to keep up with the high demand for these drugs, but there’s still not enough to go around. This week, both companies shared their quarterly results, showing how important these medications are for their financial success.

Even though Novo Nordisk’s stock has gone up by more than 350% in the last four years, it’s still selling at a 30% lower price compared to Eli Lilly’s stock. This suggests that there’s room for Novo Nordisk to grow and catch up with Eli Lilly.

25,000 patients start Wegovy weekly, up from 5,000 in December, amid supply challenges. 

Novo Nordisk is working hard to meet the growing demand for Wegovy in the United States, despite facing challenges with supply and competition from Eli Lilly. To address this, the company is investing heavily in increasing manufacturing capacity, spending around $6.4 billion, and planning to acquire three additional factories for $11 billion.

This investment is crucial as the number of patients starting on Wegovy each week has surged to over 25,000, up from 5,000 in December. However, in the first quarter, Wegovy’s sales fell short of analysts’ expectations due to pricing pressure and supply issues.

80% of Wegovy patients pay $25 or less monthly; access to lower doses is restricted.

The pricing of Wegovy and its related medicine for diabetes, Ozempic, has sparked discussions in the US.

A study from Yale University suggests that Ozempic could be produced profitably for less than $5 per month, yet it is priced at $936, while Wegovy costs $1,349. Novo Nordisk’s CFO, Karsten Munk Knudsen, mentioned that prices have decreased due to increased volume, broader insurance coverage, and competition.

Despite this, around 80% of Wegovy patients with commercial insurance in the US pay $25 or less per month. However, Novo Nordisk still limits access to lower doses of Wegovy to ensure patients can continue treatment as they progress to higher doses.

Sajda Parveen
Sajda Parveen
Sajda Praveen is a market expert. She has over 6 years of experience in the field and she shares her expertise with readers. You can reach out to her at [email protected]
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x